Of the 697 Chinese patients with NSCLC, 235 (33.7%) patients had TKIs sensitive EGFR mutations, comprising 41 (14.5%) of the 282 squamous-cell carcinomas, 155 (52.9%) of the 293 adenocarcinomas, 34 (39.5%) of the 86 adenosquamous carcinomas, 1 (9.1%) of the 11 large-cell carcinomas, 2 (11.1%) of the 18 sarcomatoid carcinomas, and 2 (28.5%) of the 7 mucoepidermoid carcinomas (Table 1). This evidence concerns the gene EGFR and adenosquamous carcinoma.